Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carl Morrison

Showing results (81-90 of 113) with videos related to

Pageof 12
Sort By:
Oncoimmunology|March 3, 2020
Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneityShumei Kato, Ryosuke Okamura, Yuichi Kumaki, et al.
Oncotarget|September 10, 2019
Development and analytical validation of a next-generation sequencing based microsatellite instability (MSI) assaySarabjot Pabla, Jonathan Andreas, Felicia L Lenzo, et al.
Oncotarget|January 11, 2019
Analysis of mutations in primary and metastatic synovial sarcomaZhuo Xing, Lei Wei, Xiaoling Jiang, et al.
Genes, Chromosomes & Cancer|July 8, 2010
A GOG 210 aCGH study of gain at 1q23 in endometrioid endometrial cancer in the context of racial disparity and outcomeCarl Morrison, Jeffrey Miecznikowski, Kathleen M Darcy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2008
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203Martin J Edelman, Dee Watson, Xiaofei Wang, et al.
Cell Cycle (Georgetown, Tex.)|July 19, 2019
TAp73 expression and P1 promoter methylation, a potential marker for chemoresponsiveness to cisplatin therapy and survival in muscle-invasive bladder cancer (MIBC)Brittany Bunch, Nithya Krishnan, Rebecca D Greenspan, et al.
Oncoimmunology|December 8, 2018
PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumabSaby George, Antonios Papanicolau-Sengos, Felicia L Lenzo, et al.
Breast Cancer Research and Treatment|November 12, 2010
Aberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical featuresGulnur Guler, Cigdem Himmetoglu, Rafael E Jimenez, et al.
European Urology|July 25, 2016
Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic PrognosticatorsLei Wei, Jianmin Wang, Erika Lampert, et al.
Nature Communications|March 4, 2021
T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitorsTakayoshi Yamauchi, Toshifumi Hoki, Takaaki Oba, et al.
Pageof 12

Showing results (81-90 of 113) with videos related to

Sort By:
Pageof 12
Oncoimmunology|March 3, 2020
Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneityShumei Kato, Ryosuke Okamura, Yuichi Kumaki, et al.
Oncotarget|September 10, 2019
Development and analytical validation of a next-generation sequencing based microsatellite instability (MSI) assaySarabjot Pabla, Jonathan Andreas, Felicia L Lenzo, et al.
Oncotarget|January 11, 2019
Analysis of mutations in primary and metastatic synovial sarcomaZhuo Xing, Lei Wei, Xiaoling Jiang, et al.
Genes, Chromosomes & Cancer|July 8, 2010
A GOG 210 aCGH study of gain at 1q23 in endometrioid endometrial cancer in the context of racial disparity and outcomeCarl Morrison, Jeffrey Miecznikowski, Kathleen M Darcy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2008
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203Martin J Edelman, Dee Watson, Xiaofei Wang, et al.
Cell Cycle (Georgetown, Tex.)|July 19, 2019
TAp73 expression and P1 promoter methylation, a potential marker for chemoresponsiveness to cisplatin therapy and survival in muscle-invasive bladder cancer (MIBC)Brittany Bunch, Nithya Krishnan, Rebecca D Greenspan, et al.
Oncoimmunology|December 8, 2018
PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumabSaby George, Antonios Papanicolau-Sengos, Felicia L Lenzo, et al.
Breast Cancer Research and Treatment|November 12, 2010
Aberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical featuresGulnur Guler, Cigdem Himmetoglu, Rafael E Jimenez, et al.
European Urology|July 25, 2016
Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic PrognosticatorsLei Wei, Jianmin Wang, Erika Lampert, et al.
Nature Communications|March 4, 2021
T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitorsTakayoshi Yamauchi, Toshifumi Hoki, Takaaki Oba, et al.
Pageof 12